{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:02:24Z","timestamp":1773496944232,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/tpj.2017.45","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T11:03:48Z","timestamp":1511262228000},"page":"487-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro"],"prefix":"10.1038","volume":"18","author":[{"given":"S","family":"Pillai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Duvvuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Farmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"E","family":"Bastyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hoogwerf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"BFtpj201745_CR1","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","volume":"142","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592\u20131609.","journal-title":"Gastroenterology"},{"key":"BFtpj201745_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","volume":"140","author":"CD Williams","year":"2011","unstructured":"Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124\u2013131.","journal-title":"Gastroenterology"},{"key":"BFtpj201745_CR3","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/hep.23527","volume":"51","author":"MS Ascha","year":"2010","unstructured":"Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN . The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972\u20131978.","journal-title":"Hepatology"},{"key":"BFtpj201745_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.24491","volume":"54","author":"N Bhala","year":"2011","unstructured":"Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208\u20131216.","journal-title":"Hepatology"},{"key":"BFtpj201745_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/hep.22726","volume":"49","author":"R Guerrero","year":"2009","unstructured":"Guerrero R, Vega GL, Grundy SM, Browning JD . Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009; 49: 791\u2013801.","journal-title":"Hepatology"},{"key":"BFtpj201745_CR6","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1053\/j.gastro.2009.01.050","volume":"136","author":"JB Schwimmer","year":"2009","unstructured":"Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136: 1585\u20131592.","journal-title":"Gastroenterology"},{"key":"BFtpj201745_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-Hansen A et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352\u2013356.","journal-title":"Nat Genet"},{"key":"BFtpj201745_CR8","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461\u20131465.","journal-title":"Nat Genet"},{"key":"BFtpj201745_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"150","author":"RM Mancina","year":"2016","unstructured":"Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 2016; 150: 1219\u20131230 e1216.","journal-title":"Gastroenterology"},{"key":"BFtpj201745_CR10","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","volume":"19","author":"P Dongiovanni","year":"2013","unstructured":"Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013; 19: 6969\u20136978.","journal-title":"World J Gastroenterol"},{"key":"BFtpj201745_CR11","doi-asserted-by":"publisher","first-page":"460190","DOI":"10.1155\/2015\/460190","volume":"2015","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni P, Romeo S, Valenti L . Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int 2015; 2015: 460190.","journal-title":"Biomed Res Int"},{"key":"BFtpj201745_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.dld.2012.12.006","volume":"45","author":"L Valenti","year":"2013","unstructured":"Valenti L, Dongiovanni P, Ginanni Corradini S, Burza MA, Romeo S . PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. Dig Liver Dis 2013; 45: 619\u2013624.","journal-title":"Dig Liver Dis"},{"key":"BFtpj201745_CR13","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.soard.2016.06.004","volume":"12","author":"M Krawczyk","year":"2016","unstructured":"Krawczyk M, Jimenez-Aguero R, Alustiza JM, Emparanza JI, Perugorria MJ, Bujanda L et al. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surg Obes Relat Dis 2016; 12: 1838\u20131846.","journal-title":"Surg Obes Relat Dis"},{"key":"BFtpj201745_CR14","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2015.07.036","volume":"63","author":"E Scorletti","year":"2015","unstructured":"Scorletti E, West AL, Bhatia L, Hoile SP, McCormick KG, Burdge GC et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. J Hepatol 2015; 63: 1476\u20131483.","journal-title":"J Hepatol"},{"key":"BFtpj201745_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/jgh.12656","volume":"30","author":"J Shen","year":"2015","unstructured":"Shen J, Wong GL, Chan HL, Chan RS, Chan HY, Chu WC et al. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2015; 30: 139\u2013146.","journal-title":"J Gastroenterol Hepatol"},{"key":"BFtpj201745_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/dom.12222","volume":"16","author":"VP Sinha","year":"2014","unstructured":"Sinha VP, Howey DC, Choi SL, Mace KF, Heise T . Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 344\u2013350.","journal-title":"Diabetes Obes Metab"},{"key":"BFtpj201745_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2337\/db13-0826","volume":"63","author":"MC Moore","year":"2014","unstructured":"Moore MC, Smith MS, Sinha VP, Beals JM, Michael MD, Jacober SJ et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2014; 63: 494\u2013504.","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"BFtpj201745_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/dom.12753","volume":"18","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Henry RR, Ciaraldi TP, Armstrong DA, Burke PM, Pettus JH et al. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes. Diabetes Obes Metab 2016; 18 (Suppl 2): 17\u201324.","journal-title":"Diabetes Obes Metab"},{"key":"BFtpj201745_CR19","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/dom.12756","volume":"18","author":"DL Russell-Jones","year":"2016","unstructured":"Russell-Jones DL . Hepato-preferential insulins: is this the end, or the end of the beginning? Diabetes Obes Metab 2016; 18: 1053\u20131054.","journal-title":"Diabetes Obes Metab"},{"key":"BFtpj201745_CR20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/dom.12698","volume":"18","author":"RM Bergenstal","year":"2016","unstructured":"Bergenstal RM, Lunt H, Franek E, Travert F, Mou J, Qu Y et al. Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab 2016; 18: 1081\u20131088.","journal-title":"Diabetes Obes Metab"},{"key":"BFtpj201745_CR21","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/dom.12696","volume":"18","author":"T Blevins","year":"2016","unstructured":"Blevins T, Pieber TR, Colon Vega G, Zhang S, Bastyr EJ 3rd, Chang AM et al. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. Diabetes Obes Metab 2016; 18: 1072\u20131080.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"BFtpj201745_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/dom.12738","volume":"18","author":"S Garg","year":"2016","unstructured":"Garg S, Dreyer M, Jinnouchi H, Mou J, Qu Y, Hartman ML et al. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1. Diabetes Obes Metab 2016; 18 (Suppl 2): 25\u201333.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"BFtpj201745_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/dom.12740","volume":"18","author":"S Garg","year":"2016","unstructured":"Garg S, Selam JL, Bhargava A, Schloot N, Luo J, Zhang Q et al. Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study. Diabetes Obes Metab 2016; 18 (Suppl 2): 43\u201349.","journal-title":"Diabetes Obes Metab"},{"key":"BFtpj201745_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/dom.12754","volume":"18","author":"H Ginsberg","year":"2016","unstructured":"Ginsberg H, Cariou B, Orchard T, Chen L, Luo J, Bastyr EJ 3rd et al. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials. Diabetes Obes Metab 2016; 18: 1089\u20131092.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"BFtpj201745_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.12743","volume":"18","author":"G Grunberger","year":"2016","unstructured":"Grunberger G, Chen L, Rodriguez A, Tinahones FJ, Jacober SJ, Bue-Valleskey J et al. A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naive patients with type 2 diabetes: the IMAGINE 6 trial. Diabetes Obes Metab 2016; 18 (Suppl 2): 34\u201342.","journal-title":"Diabetes Obes Metab"},{"key":"BFtpj201745_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2337\/dc15-1531","volume":"39","author":"JB Buse","year":"2016","unstructured":"Buse JB, Rodbard HW, Trescoli Serrano C, Luo J, Ivanyi T, Bue-Valleskey J et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care 2016; 39: 92\u2013100.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"BFtpj201745_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/dom.12751","volume":"18","author":"K Cusi","year":"2016","unstructured":"Cusi K, Sanyal AJ, Zhang S, Hoogwerf BJ, Chang AM, Jacober SJ et al. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. Diabetes Obes Metab 2016; 18 (Suppl 2): 50\u201358.","journal-title":"Diabetes Obes Metab"},{"key":"BFtpj201745_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/dom.12712","volume":"18","author":"MJ Davies","year":"2016","unstructured":"Davies MJ, Russell-Jones D, Selam JL, Bailey TS, Kerenyi Z, Luo J et al. Basal insulin peglispro versus insulin glargine in insulin-naive type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab 2016; 18: 1055\u20131064.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"BFtpj201745_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s12072-013-9480-x","volume":"7","author":"A Duseja","year":"2013","unstructured":"Duseja A, Chalasani N . Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatol Int 2013; 7 (Suppl 2): 755\u2013764.","journal-title":"Hepatol Int"},{"key":"BFtpj201745_CR30","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1210\/jc.2015-1966","volume":"100","author":"P Portillo-Sanchez","year":"2015","unstructured":"Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 2015; 100: 2231\u20132238.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFtpj201745_CR31","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/jmri.23928","volume":"37","author":"A Mashhood","year":"2013","unstructured":"Mashhood A, Railkar R, Yokoo T, Levin Y, Clark L, Fox-Bosetti S et al. Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. J Magn Reson Imaging 2013; 37: 1359\u20131370.","journal-title":"J Magn Reson Imaging"},{"key":"BFtpj201745_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2307\/2532296","volume":"48","author":"SW Guo","year":"1992","unstructured":"Guo SW, Thompson EA . Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992; 48: 361\u2013372.","journal-title":"Biometrics"},{"key":"BFtpj201745_CR33","doi-asserted-by":"crossref","unstructured":"Johansen RF, S\u00f8ndergaard E, Linnebjerg H, Garhyan P, Lam EC et al. Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes. Diabetes Obes Metab; advance online publication, 17 August 2017; doi: 10.1111\/dom.13087 [e-pub ahead of print].","DOI":"10.1111\/dom.13087"},{"key":"BFtpj201745_CR34","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1074\/jbc.M109.064501","volume":"285","author":"S He","year":"2010","unstructured":"He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706\u20136715.","journal-title":"J Biol Chem"},{"key":"BFtpj201745_CR35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.bbalip.2013.12.006","volume":"1841","author":"P Pingitore","year":"2014","unstructured":"Pingitore P, Pirazzi C, Mancina RM, Motta BM, Indiveri C, Pujia A et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta 2014; 1841: 574\u2013580.","journal-title":"Biochim Biophys Acta"},{"key":"BFtpj201745_CR36","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3945\/jn.115.210633","volume":"145","author":"A Mondul","year":"2015","unstructured":"Mondul A, Mancina RM, Merlo A, Dongiovanni P, Rametta R, Montalcini T et al. PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity. J Nutr 2015; 145: 1687\u20131691.","journal-title":"J Nutr"},{"key":"BFtpj201745_CR37","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1093\/hmg\/ddu121","volume":"23","author":"C Pirazzi","year":"2014","unstructured":"Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 2014; 23: 4077\u20134085.","journal-title":"Hum Mol Genet"},{"key":"BFtpj201745_CR38","doi-asserted-by":"publisher","first-page":"E1568","DOI":"10.1210\/jc.2015-2978","volume":"100","author":"M Kovarova","year":"2015","unstructured":"Kovarova M, Konigsrainer I, Konigsrainer A, Machicao F, Haring HU, Schleicher E et al. The genetic variant I148M in PNPLA3 is associated with increased hepatic retinyl-palmitate storage in humans. J Clin Endocrinol Metab 2015; 100: E1568\u2013E1574.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFtpj201745_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2337\/diabetes.55.01.06.db05-0982","volume":"55","author":"EE Kershaw","year":"2006","unstructured":"Kershaw EE, Hamm JK, Verhagen LA, Peroni O, Katic M, Flier JS . Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes 2006; 55: 148\u2013157.","journal-title":"Diabetes"},{"key":"BFtpj201745_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1530\/eje.1.02229","volume":"155","author":"M Moldes","year":"2006","unstructured":"Moldes M, Beauregard G, Faraj M, Peretti N, Ducluzeau PH, Laville M et al. Adiponutrin gene is regulated by insulin and glucose in human adipose tissue. Eur J Endocrinol 2006; 155: 461\u2013468.","journal-title":"Eur J Endocrinol"},{"key":"BFtpj201745_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng.2926","volume":"46","author":"OL Holmen","year":"2014","unstructured":"Holmen OL, Zhang H, Fan Y, Hovelson DH, Schmidt EM, Zhou W et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014; 46: 345\u2013351.","journal-title":"Nat Genet"},{"key":"BFtpj201745_CR42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15403\/jgld-1276","volume":"23","author":"A Kempinska-Podhorodecka","year":"2014","unstructured":"Kempinska-Podhorodecka A, Krawczyk M, Klak M, Blatkiewicz M, Lammert F, Milkiewicz P et al. Healthy PNPLA3 risk allele carriers present with unexpected body fat composition. A study of one thousand subjects. J Gastrointestin Liver Dis 2014; 23: 33\u201337.","journal-title":"J Gastrointestin Liver Dis"},{"key":"BFtpj201745_CR43","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/hep.28142","volume":"62","author":"CJ Pirola","year":"2015","unstructured":"Pirola CJ, Sookoian S . The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis. Hepatology 2015; 62: 1742\u20131756.","journal-title":"Hepatology"},{"key":"BFtpj201745_CR44","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jhep.2014.02.017","volume":"60","author":"QM Anstee","year":"2014","unstructured":"Anstee QM, Jaques B, Hudson M, Reeves HL . Reply to \"Hepatocellular carcinoma and the Newcastle-upon-Tyne area\". J Hepatol 2014; 60: 1330\u20131331.","journal-title":"J Hepatol"},{"key":"BFtpj201745_CR45","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1194\/jlr.P067454","volume":"58","author":"M Krawczyk","year":"2017","unstructured":"Krawczyk M, Rau M, Schattenberg JM, Bantel H, Pathil A, Demir M et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res 2017; 58: 247\u2013255.","journal-title":"J Lipid Res"},{"key":"BFtpj201745_CR46","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jhep.2016.07.045","volume":"65","author":"PK Luukkonen","year":"2016","unstructured":"Luukkonen PK, Zhou Y, Hyotylainen T, Leivonen M, Arola J, Orho-Melander M et al. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol 2016; 65: 1263\u20131265.","journal-title":"J Hepatol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/tpj201745.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201745","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/tpj.2017.45","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201745.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:48:04Z","timestamp":1684622884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["BFtpj201745"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2017.45","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]},"assertion":[{"value":"30 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest. SP, SD, PB, WF, MF, SS, CH, BH and AH are employees and shareholders of Eli Lilly and Company. EB was an employee of Eli Lilly and Company during the trial and is currently a consultant to Viacyte, San Diego, CA, USA.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}